These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 19888723)

  • 1. Chemical control over immune recognition: a class of antibody-recruiting small molecules that target prostate cancer.
    Murelli RP; Zhang AX; Michel J; Jorgensen WL; Spiegel DA
    J Am Chem Soc; 2009 Dec; 131(47):17090-2. PubMed ID: 19888723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules.
    Zhang AX; Murelli RP; Barinka C; Michel J; Cocleaza A; Jorgensen WL; Lubkowski J; Spiegel DA
    J Am Chem Soc; 2010 Sep; 132(36):12711-6. PubMed ID: 20726553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Single-Domain Antibody-Based Anti-PSMA Recombinant Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Therapy.
    Xing Y; Xu K; Li S; Cao L; Nan Y; Li Q; Li W; Hong Z
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation and Evaluation of Radiolabeled Antibody Recruiting Small Molecules That Target Prostate-Specific Membrane Antigen for Combined Radiotherapy and Immunotherapy.
    Genady AR; Janzen N; Banevicius L; El-Gamal M; El-Zaria ME; Valliant JF
    J Med Chem; 2016 Mar; 59(6):2660-73. PubMed ID: 26894427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen.
    Wang X; Ma D; Olson WC; Heston WD
    Mol Cancer Ther; 2011 Sep; 10(9):1728-39. PubMed ID: 21750220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody recruiting small molecules: a new option for prostate tumor therapy by PSMA targeting.
    Küchenthal CH; Maison W
    Chembiochem; 2010 May; 11(8):1052-4. PubMed ID: 20432428
    [No Abstract]   [Full Text] [Related]  

  • 7. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
    Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U
    Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer.
    Su Y; Liu Y; Behrens CR; Bidlingmaier S; Lee NK; Aggarwal R; Sherbenou DW; Burlingame AL; Hann BC; Simko JP; Premasekharan G; Paris PL; Shuman MA; Seo Y; Small EJ; Liu B
    JCI Insight; 2018 Sep; 3(17):. PubMed ID: 30185663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical nature and mapping of PSMA epitopes recognized by human antibodies induced after immunization with gene-based vaccines.
    Todorova K; Zoubak S; Mincheff M; Kyurkchiev S
    Anticancer Res; 2005; 25(6C):4727-32. PubMed ID: 16334167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New platinum(II) complexes conjugated at position 7α of 17β-acetyl-testosterone as new combi-molecules against prostate cancer: design, synthesis, structure-activity relationships and biological evaluation.
    Fortin S; Brasseur K; Morin N; Asselin É; Bérubé G
    Eur J Med Chem; 2013 Oct; 68():433-43. PubMed ID: 23994871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth.
    Su Y; Yu L; Liu N; Guo Z; Wang G; Zheng J; Wei M; Wang H; Yang AG; Qin W; Wen W
    Cancer Lett; 2013 Sep; 338(2):282-91. PubMed ID: 23752065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A chemically induced vaccine strategy for prostate cancer.
    Dubrovska A; Kim C; Elliott J; Shen W; Kuo TH; Koo DI; Li C; Tuntland T; Chang J; Groessl T; Wu X; Gorney V; Ramirez-Montagut T; Spiegel DA; Cho CY; Schultz PG
    ACS Chem Biol; 2011 Nov; 6(11):1223-31. PubMed ID: 21936526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer.
    Cho S; Zammarchi F; Williams DG; Havenith CEG; Monks NR; Tyrer P; D'Hooge F; Fleming R; Vashisht K; Dimasi N; Bertelli F; Corbett S; Adams L; Reinert HW; Dissanayake S; Britten CE; King W; Dacosta K; Tammali R; Schifferli K; Strout P; Korade M; Masson Hinrichs MJ; Chivers S; Corey E; Liu H; Kim S; Bander NH; Howard PW; Hartley JA; Coats S; Tice DA; Herbst R; van Berkel PH
    Mol Cancer Ther; 2018 Oct; 17(10):2176-2186. PubMed ID: 30065100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Saporin toxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity.
    Kuroda K; Liu H; Kim S; Guo M; Navarro V; Bander NH
    Prostate; 2010 Sep; 70(12):1286-94. PubMed ID: 20623630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-Specific Membrane Antigen-Specific Antitumor Activity of a Self-Immolative Tubulysin Conjugate.
    Leamon CP; Reddy JA; Bloomfield A; Dorton R; Nelson M; Vetzel M; Kleindl P; Hahn S; Wang K; Vlahov IR
    Bioconjug Chem; 2019 Jun; 30(6):1805-1813. PubMed ID: 31075200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen.
    Huang X; Bennett M; Thorpe PE
    Prostate; 2004 Sep; 61(1):1-11. PubMed ID: 15287089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer.
    Murga JD; Moorji SM; Han AQ; Magargal WW; DiPippo VA; Olson WC
    Prostate; 2015 Feb; 75(3):242-54. PubMed ID: 25327687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system.
    Arndt C; Feldmann A; Koristka S; Cartellieri M; Dimmel M; Ehninger A; Ehninger G; Bachmann M
    Prostate; 2014 Sep; 74(13):1335-46. PubMed ID: 25053443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion.
    Conrad F; Zhu X; Zhang X; Chalkley RJ; Burlingame AL; Marks JD; Liu B
    J Mol Med (Berl); 2009 May; 87(5):507-14. PubMed ID: 19219419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.
    McDevitt MR; Barendswaard E; Ma D; Lai L; Curcio MJ; Sgouros G; Ballangrud AM; Yang WH; Finn RD; Pellegrini V; Geerlings MW; Lee M; Brechbiel MW; Bander NH; Cordon-Cardo C; Scheinberg DA
    Cancer Res; 2000 Nov; 60(21):6095-100. PubMed ID: 11085533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.